Skip to content

Medical Grand Rounds: Results of the Glycemia Reduction Approaches in Diabetes Study

In This Article

  • A recent virtual Medical Grand Rounds presentation was led by the Endocrine Division at Massachusetts General Hospital
  • The Division presented major results of the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness (GRADE) study
  • The GRADE study tested the effectiveness of four FDA-approved glucose-lowering medications when added to metformin

The Endocrine Division at Massachusetts General Hospital led a virtual Department of Medicine Medical Grand Rounds presentation on June 15, 2023.

The Division presented major results from the Glycemia Reduction Approaches in Diabetes—A Comparative Effectiveness (GRADE) study, designed to help guide the choice of glucose-lowering medications that would be added to metformin. Four FDA-approved glucose-lowering medications were included: glimepiride, sitagliptin, liraglutide, and glargine.

The panel included David M. Nathan, MD, director of the Diabetes Clinical Research Center at Mass General, Deborah J. Wexler, MD, MSc, associate clinical chief of the Diabetes Unit and clinical director of the Diabetes Center.

Watch the video »

Learn more about the Diabetes Unit

Refer a patient to the Endocrinology Division

Related topics


The novel iLet® Bionic Pancreas, developed and tested by Massachusetts General Hospital researchers, simplifies diabetes management and leads to better glucose control than currently available methods.


Melissa S. Putman, MD, and colleagues found measures of hyperglycemia and glycemic variability provided by continuous glucose monitors were superior to hemoglobin A1c in distinguishing between patients with cystic fibrosis (CF) who did and did not have CF-related diabetes.